Purpose: To evaluate the efficacy of a dexamethasone intravitreal implant in combination with intravitreal anti-vascular endo-
Introduction
Age-related macular degeneration (AMD) is a leading cause of vision loss in people aged 50 or older in the United States. [1] [2] [3] Neovascular AMD (nvAMD) accounts for the majority of the visual impairment in these patients. 4 Choroidal neovascularization (CNV) is the hallmark of nvAMD and results in welldescribed leakage, exudation, and hemorrhage in the macula, which can produce rapid vision loss. 5 The role of vascular endothelial growth factor (VEGF) in CNV formation and maintenance is well established, 6, 7 and intravitreal anti-VEGF agents have become the first-line treatment and standard of care for nvAMD over the past decade. [8] [9] [10] Today, 3 agents, bevacizumab (Avastin; Genentech, San Francisco, California), ranibizumab (Lucentis; Genentech), and aflibercept (Eylea/ VEGF Trap-Eye; Regeneron, Tarrytown, New York), are in the clinical use. Despite the efficacy of anti-VEGF therapy, a subset of patients do not optimally respond and have persistent subretinal or intraretinal fluid with vision loss despite anti-VEGF monotherapy. [11] [12] [13] Treatment of these patients is challenging and may include any combination of switching among anti-VEGF agents, [14] [15] [16] use of photodynamic therapy (PDT), 17 or use of intravitreal corticosteroids. 18, 19 Corticosteroids are an attractive adjuvant for treatmentresistant nvAMD because they address the inflammatory component of CNV membrane formation and growth that is not targeted by anti-VEGF agents. Multiple studies have shown that inflammatory elements, including macrophages, play an important role in AMD progression. [20] [21] [22] Steroids stabilize vascular tight junctions and decrease leakage, 23 produce apoptosis of peripheral T-cells 24 and eosinophils, 25 and may block fibroblast activation and proliferation. 26 In addition, glucocorticoids have been shown to directly inhibit VEGF production. 27 Dexamethasone is a potent steroid, but its clinical usefulness is limited by its rapid clearance from the vitreous cavity (ie, 3 half-lives of <12 hours). 28 The dexamethasone intravitreal implant (0.7 mg Ozurdex; Allergan, Parsippany, New Jersey) allows steady dexamethasone delivery in the vitreous cavity over a period of up to 6 months via a sustained-release injectable biopolymer with dexamethasone integrated with polylactic-co-glycolic acid. 29, 30 It is approved by the US Food and Drug Administration for the treatment of diabetic macular edema, cystoid macular edema associated with retinal vein occlusion, and noninfectious uveitis. 31 The dexamethasone implant is well suited for the treatment of chronic, inflammatory macular diseases.
Recently, Kuppermann and colleagues 32 conducted a 6month, single-masked, multicenter study in which patients with nvAMD were randomized to receive either dexamethasone intravitreal implant or sham and 2 intravitreal ranibizumab injections. They showed that the intravitreal dexamethasone implant increased the injection-free interval of anti-VEGF therapy but did not change visual acuity or retinal thickness outcomes. 32 Although their study groups included both patients previously receiving anti-VEGF therapy as well as treatmentnaive patients with nvAMD, they did not examine the effect of the dexamethasone intravitreal implant in patients with suboptimal responses to anti-VEGF monotherapy, which is a likely scenario that would necessitate treatment beyond anti-VEGF agents in the real world. 32 
Methods
The study herein is a single-center, interventional, retrospective consecutive case series. It was conducted with the approval of the institutional review board and in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 2000 and 2008.
Study Patient Population and Inclusion/Exclusion Criteria
We conducted a retrospective chart review of clinical data of consecutive patients with treatment-resistant nvAMD who underwent dual therapy with anti-VEGF medication and the dexamethasone intravitreal implant concurrently at Associated Retinal Consultants, Royal Oak, Michigan, between 2012 and 2016. To be eligible for the study, patients were required to meet the following inclusion criteria ( Table 1) : age > 50, diagnosis of nvAMD with active subfoveal CNV (as determined by clinical examination, spectral domain optical coherence tomography [SD-OCT], fluorescein angiography [FA], and bestcorrected visual acuity [BCVA] of 20/30 to 20/800). Patients previously treated with PDT or intravitreal triamcinolone acetonide injections were included as long as they received treatment more than 6 months prior to the dual therapy. Patients were required to have received at least 2 anti-VEGF intravitreal injections that showed treatment resistance and have a minimum of 3 months of follow-up. Treatment-resistant nvAMD was defined as (1) persistent intraretinal or subretinal fluid despite monthly injections, (2) included prior diagnosis of glaucoma or advanced cupping, history of intraocular pressure (IOP), steroid response to local or systemic steroids, and history of elevated IOP requiring topical therapy or glaucoma surgery. Patients with CNV from any cause other than nvAMD were excluded. Patients were also excluded if they had active diabetic retinopathy, retinal vein occlusion, active ocular infection, aphakia or pseudophakia with an anterior chamber intraocular lens, or scleral-fixated intraocular lens (Table 1 ).
Intervention
The dual therapy was administered in patients with treatmentresistant nvAMD after discussion of the off-label use of the dexamethasone intravitreal implant. All patients were counseled on the risks of potential injection-related complications such as endophthalmitis, cataract progression (if phakic), and IOP elevation. All patients received local anesthesia in the form of subconjunctival lidocaine 2% without epinephrine and were prepped with 5% betadine to the injection sites with the aid of an eyelid speculum. First, the anti-VEGF agent was administered followed by injection of the dexamethasone intravitreal implant using the aseptic technique. A sterile cotton-tipped applicator was applied to facilitate closure of the sclerotomy, and the eye was irrigated with balanced salt solution and given a drop of topical antibiotic. All patients received the same anti-VEGF agent they were receiving prior to dual therapy at the time of intravitreal dexamethasone implant injection and continued to receive anti-VEGF injections of the same agent thereafter at the discretion of the treating physician.
For patients who met the inclusion criteria, BCVA and multimodal imaging data (SD-OCT, fundus photography, fundus autofluorescence, and FA) were collected and analyzed at every visit (Table 2 ). In addition, key safety data including IOP changes, worsening or new cataract formation, posterior segment complications, endophthalmitis, and any implant-related complications in the course of follow-up were reviewed from patients' medical records (Table 3 ).
Statistics and Data Analysis
Best-corrected visual acuity, CFT, and MCV data were collected, and changes in these parameters were determined at the first visit after dual therapy was begun and at the visit following the last monotherapy anti-VEGF injection prior to the dual therapy. The clinical responses of 3 index patients to anti-VEGF monotherapy and subsequent dual therapy are summarized with their FA, OCT, and BCVA data in Figures 1, 2 and 3. The mean differences in CFT ( Figure 4 ) and MCV ( Figure 5 ) were evaluated for statistical significance using a paired t test. Snellen visual acuities were converted to logarithm of the minimum angle of resolution (logMAR) equivalents and their means compared using a 2-way analysis of variance with multiple comparisons ( Figure 6 ). The correlation using a Pearson coefficient between the total number of injections and the change in CFT after dual therapy is summarized in Figure 7 . The total number of anti-VEGF injections required the 6 months before and after the dual therapy with the dexamethasone intravitreal implant was determined and the injection-free interval computed ( Figure 8 ). All statistical comparisons were performed using GraphPad Prism software (LaJolla, California). For all comparisons, statistical significance was P < .05.
Results
Eighteen eyes of 18 consecutive patients met the inclusion criteria and were included in the study ( Table 1 ). The cohort represented all eyes that received dual therapy. Participants had a mean age of 81.5 years (range, 67-91 years), 8 (44.4%) were male and 10 (55.6%) were female (Table 2) , and all were Caucasian. Most eyes were pseudophakic (16 or 88.9%), whereas only 2 (11.1%) were phakic. Patients underwent a mean of 26.3 anti-VEGF injections (range, 2-56) prior to having dual therapy with the dexamethasone intravitreal implant. Prior treatments included injections of bevacizumab, ranibizumab, or aflibercept, with 17 (94.4%) patients having received at least 2 different drugs in their course of prior treatment and 1 patient having received a series of 6 ranibizumab injections only before dual therapy. Only 2 (11.1%) patients had prior PDT and 2 (11.1%) had intravitreal triamcinolone acetonide, all of which occurred at least 6 months before dual therapy. The mean length of follow-up was 8.2 months (range, 4-14.2 months). The dexamethasone intravitreal implant dual therapy was overall well tolerated; the frequency of adverse effects is summarized in Table 3 . Transient IOP elevation effectively treated with topical glaucoma drops developed in 2 (11.1%) of patients. None of the patients required glaucoma surgery. One patient with preexisting cataract developed worsening cataract and became symptomatic. This patient underwent successful cataract extraction without complications. There were no cases of endophthalmitis, vitreous hemorrhage, or implant-related complications. Figures 1, 2 , and 3 summarize clinical data from 3 index patients included in the series. The first is an 87-year-old pseudophakic Caucasian woman with nvAMD and active CNV ( Figure 1A reduction in mean CFT of 126.3 mm compared to a mean increase in mean CFT of 29.9 mm with anti-VEGF treatment alone. This difference was statistically significant (P ¼ .0017). Furthermore, as a result of combined treatment, there was a statistically significant reduction in MCV of À0.85 mm 3 compared to a mean increase in MCV of 0.19 mm 3 with anti-VEGF treatment alone (P ¼ .0014). Figure 6 summarizes the visual acuity data. Anti-VEGF therapy alone did not produce significant mean change in log-MAR BCVA. Dual therapy with the dexamethasone intravitreal implant resulted in a small trend toward improvement of mean BCVA, but the difference was not statistically significant (P ¼ .92). Although there was no change in mean BCVA, vision improved by at least 1 line in 6 (33.3%) of patients as a result of dual therapy.
Patients who had improvement in BCVA as a result of combined treatment had a lower mean number of prior anti-VEGF injections (21.0 vs 28.9), which may suggest that earlier treatment is beneficial. To investigate this, we performed a correlation analysis between the change in CFT and the number of anti-VEGF injections as a surrogate marker of baseline nvAMD disease duration. There was mild-moderate correlation between the number of prior anti-VEGF injections and the likelihood of CFT reduction in response to dual therapy (Figure 7) with the Pearson correlation coefficient (r ¼ .375). In addition, dual therapy significantly reduced the number of required anti-VEGF injections after combined injections (Figure 8 ). The mean total number of injections during the 6 months before dual therapy (5.33) was significantly greater than the total number of injections during the 6 months after dual therapy (4.25) with P ¼ .0199 ( Figure 8A ). In addition, the mean treatment-free interval between injections before (1.13 months) was significantly extended to 1.74 months as a result of dual therapy ( Figure 8B, P ¼ .0312 ).
Discussion
Over the past decade, anti-VEGF therapy has become the standard of care for the treatment of nvAMD. Despite the success of anti-VEGF agents, a significant proportion of eyes with nvAMD will demonstrate partial or no treatment response demonstrated by persistent intraretinal or subretinal fluid. In the Comparison of Age-Related Macular Degeneration Treatment Trial, up to 50% of patients on monthly anti-VEGF therapy had persistent fluid on OCT. 10, 33 Although the majority of these ''incomplete responders'' retained good vision with continued anti-VEGF therapy, 34 patients with persistent fluid associated with macular exudation, hemorrhage, and/or worsening vision despite monthly anti-VEGF therapy can be classified as having treatment-resistant nvAMD and are at risk for vision loss. It can be a challenge for physicians to get complete resolution of the fluid after many injections and a variety of treatment strategies have been employed. These include switching anti-VEGF agents, 14, [35] [36] [37] increasing the injection dose or frequency, 38, 39 and combining anti-VEGF therapy with PDT 40 and/or intravitreal steroids. 41, 42 Combination therapy with intravitreal steroids may simultaneously address both angiogenic (VEGF-mediated) and inflammatory mechanisms of CNV and its associated intraretinal and subretinal fluids. 43, 44 Although it was used before in nvAMD eyes because of its high potency, 41, 42 intravitreal dexamethasone given as a single injection has limited clinical usefulness because of its very short half-life. 28 The dexamethasone intravitreal implant, however, offers sustained release of dexamethasone in the vitreous cavity with a clinically meaningful effect of 3 to 4 months' duration. In this study, we report a case series of consecutive patients with nvAMD undergoing treatment resistance to anti-VEGF monotherapy who were then treated with dual therapy of the same anti-VEGF agent plus the off-label use of the dexamethasone intravitreal implant. This is a consecutive series that presents the data from every patient that received dual therapy for persistently active nvAMD. Patients enrolled in the study met strict inclusion criteria and were consistently managed. The patients had a significant decrease in CFT and MCV after a single dual therapy. There was a mild to moderate correlation between CFT change and the number of prior anti-VEGF injections, suggesting that earlier treatment with dual therapy may result in a more significant anatomic response. Although visual improvement of at least 1 line of BCVA was observed in one-third of patients, the mean visual acuity gains did not reach statistical significance. It is possible that earlier treatment with the dexamethasone intravitreal implant, along with continued anti-VEGF treatment may have increased the likelihood of a more significant visual improvement, but this question requires further study with a larger sample size of patients. Dual therapy resulted in a small but significant reduction in the mean number of required injections and resulted in a significant extension in the treatmentfree interval. In 1 patient, we were able to eliminate persistent intraretinal fluid and get the patient off the anti-VEGF injections completely. This suggests that dual therapy may reduce treatment burden in nvAMD as was suggested previously. 32 It is also potentially possible that earlier initiation of dual therapy would have shown a greater effect in reducing the subsequent treatment burden also. Unfortunately, the number of patients was too small to adequately comment on differences in response of eyes with intraretinal fluid with a frank cystoid appearance to those that had predominately subretinal fluid and less or no cystoid macular edema as part of the nvAMD complex.
Overall, dual therapy with the intravitreal dexamethasone implant was well tolerated, but it produced the predictable effect of worsening cataract and mild IOP elevation (managed with drops alone) in a small subset of patients, which is consistent with the reported side effects of this agent. 45, 46 There were no implant-related or same day double injection-related complications.
The limitations of this study include its retrospective design, small sample size, and lack of the control group. In addition, the patient cohort had a heterogeneous treatment history with varied durations of therapy. This likely reflected the variability of the underlying biology of disease in each patient, including the variability in type and size of the choroidal neovascular lesions. These metrics were not measured as doing so was beyond the intent and scope of our study. Conversely, the study was done at a single center with relatively homogenous, predominantly Caucasian population, its results may not necessarily be applied to other races, which may respond differently to intravitreal anti-VEGF and/or steroid therapy, and may have higher rates of nvAMD variants such as polypoidal choroidal vasculopathy. Finally, the response to the combined treatment is still difficult to predict as there are no widely available direct measurements of the inflammatory activity in eyes with active CNV lesions. The development of biomarker assays for nvAMD treatment nonresponders will be important to help us adequately stratify patients that would benefit most from combined therapy.
The simultaneous use of the dexamethasone intravitreal implant in combination with anti-VEGF therapy for nvAMD may be a safe and effective treatment option for eyes resistant to anti-VEGF monotherapy with persistent intraretinal or subretinal fluid. Earlier treatment with such dual therapy may maximize anatomic and visual outcomes and reduce the treatment burden. We look forward to the continued evaluation of dual therapy as a treatment for treatment-resistant nvAMD through larger, prospective multicenter trials. This will allow us to better understand which patients are the best candidates for such intervention and hopefully lead to earlier intervention. We also look forward to the development of safe, straightforward methods of clinical assessment of inflammatory cytokines in eyes receiving intravitreal injection therapy with the hope that they will correlate with responses to therapy with agents that act through different mechanisms and so treatment paradigms may be more specifically titrated for each individual patient.
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